Literature DB >> 12789126

Childhood bacterial meningitis in Mbarara Hospital, Uganda: antimicrobial susceptibility and outcome of treatment.

J P Kiwanuka1, J Mwanga.   

Abstract

BACKGROUND: The recommended antibiotic treatment of bacterial meningitis has come under scrutiny following frequent reports of in-vitro resistance by the common causative organisms to penicillin and chloramphenicol.
OBJECTIVE: The study recorded the causative organisms, antibiotic sensitivity patterns and outcome of treatment of bacterial meningitis in children and examined the impact of various factors on the recorded outcome.
DESIGN: This was a retrospective review of all case records of patients treated for bacterial meningitis over a one year period.
SETTING: The study was set in the paediatric wards of Mbarara University Teaching Hospital, in south western Uganda.
RESULTS: A total of 77 patients were treated. Among 56 patients with available CSF results the frequency of bacterial causes was as follows: H. influenzae 13(23.2%), coliforms 7(12.5%), uncultured Gram-negative bacilli 7(12.5%), S. pneumoniae 5(8.9%) and N. meningitidis 3(5.4%). Most isolates tested were resistant to both penicillin and chloramphenicol, but all were sensitive to ciprofloxacin and perfloxacin. Twenty eight(36.8%) patients died, 22(28.9%) survived with sequelae and 15(19.7%) improved without sequelae. 14/18 who received perfloxacin and/or ciprofloxacin survived compared with 23/47 who did not: p=0.04).
CONCLUSIONS: The high case-fatality rates and the high frequency of resistance to penicillin and chloramphenicol make a case for a review of the currently recommended antibiotic treatment of bacterial meningitis in this region. Fluoroquinolones need further evaluation as potential alternatives to chloramphenicol in the treatment of bacterial meningitis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12789126      PMCID: PMC2704445     

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


  6 in total

1.  Cefotaxime versus penicillin-chloramphenicol in purulent meningitis: a controlled single-blind clinical trial.

Authors:  I E Haffejee
Journal:  Ann Trop Paediatr       Date:  1988-12

2.  Response to antimicrobial therapy in childhood bacterial meningitis in tropical Africa: report of a bi-centre experience in Nigeria, 1993-1998.

Authors:  G O Akpede; S O Dawodu; M E Umoffia
Journal:  Ann Trop Paediatr       Date:  1999-09

Review 3.  Childhood bacterial meningitis beyond the neonatal period in southern Nigeria: changes in organisms/antibiotic susceptibility.

Authors:  O Akpede; P O Abiodun; M Sykes; C E Salami
Journal:  East Afr Med J       Date:  1994-01

Review 4.  Management of infections caused by antibiotic-resistant Streptococcus pneumoniae.

Authors:  I R Friedland; G H McCracken
Journal:  N Engl J Med       Date:  1994-08-11       Impact factor: 91.245

5.  Bacterial meningitis in children in southern Ghana.

Authors:  J O Commey; O P Rodrigues; F A Akita; M Newman
Journal:  East Afr Med J       Date:  1994-02

6.  Failure of chloramphenicol therapy in penicillin-resistant pneumococcal meningitis.

Authors:  I R Friedland; K P Klugman
Journal:  Lancet       Date:  1992-02-15       Impact factor: 79.321

  6 in total
  3 in total

1.  A situational analysis of antimicrobial drug resistance in Africa: are we losing the battle?

Authors:  Andrew Nyerere Kimang'a
Journal:  Ethiop J Health Sci       Date:  2012-07

2.  Intraventricular ciprofloxacin usage in treatment of multidrug-resistant central nervous system infections: report of four cases.

Authors:  Ayşe Karaaslan; Eda Kepenekli Kadayifçi; Ozden Turel; Demet Gedikbaşi Toprak; Ahmet Soysal; Mustafa Bakir
Journal:  Pediatr Rep       Date:  2014-12-12

3.  Aetiology and Outcomes of Suspected Infections of the Central Nervous System in Children in Mbarara, Uganda.

Authors:  Anne-Laure Page; Yap Boum Ii; Elizabeth Kemigisha; Nicolas Salez; Deborah Nanjebe; Céline Langendorf; Said Aberrane; Dan Nyehangane; Fabienne Nackers; Emmanuel Baron; Rémi Charrel; Juliet Mwanga-Amumpaire
Journal:  Sci Rep       Date:  2017-06-02       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.